A new and exciting treatment
Today it was announced that the NHS has treated the first patient with potentially life-saving gene therapy that can prevent paralysis and prolong the lives of children with Spinal Muscular Atrophy, as the NHS Long Term Plan continues to provide the best possible healthcare solutions for patients.
- The NHS Long Term Plan committed to using cutting edge treatments and therapies to save and improve patients’ lives and provide access to the latest generation of innovative medicines through the NHS.
- Last week the NHS was able to treat the first patient, a five-month old baby, with one-off gene therapy - a revolutionary treatment called Zolgensma which is now available for babies and children on the NHS – offering the best possible treatment to give babies and children with SMA the best possible future.
- This is just the latest example of our brilliant life sciences industry working hand in hand with the NHS to put patients first, offering a renewed hope that more children’s lives can be transformed.
Comments